Clinical trial · Interventional
PApillomavirus in REnal Transplant Patient
Study of the Distribution of Genotypes of HPV at the Ano-genital Area and Peripheral Humoral Immune Response Before and After Kidney Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main goal of project is to study the distribution of HPV genotypes in the anogenital area and peripheral humoral immune responses HPV (total and neutralizing Ab) before and after renal transplantation. Furthermore, the investigators wish (i) establish whether there is a correlation between HPV infection and HPV immune response before and after transplantation, and (ii) determine whether there is a link between HPV infection and immunosuppression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillomavirus Infections | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Kidney transplanted patients | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- kidney transplanted patient
- interventionNames
- Other: Kidney transplanted patients
Primary outcomes (1)
- measure
- Prevalence of genital HPV infection before and after kidney transplantation in man and women
- timeFrame
- 12 months
- description
- For woman, gynecologist perform cervical and anal samples with DNA pap cervical sampler. For men, dermatologist perform penis and anal samples with same device. The sample with perform when the patient are registered to waiting list for transplant and 3 months and one year after transplantation. The samples are genotyped using the kit INNO-LiPA HPV Genotyping Extra test (Innogenetics) which allows the detection of 28 HPV types.
Secondary outcomes (2)
- measure
- Anti-HPV 16 Antibody titer in blood before and after kidney transplantation in man and women
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged over 18 years * Patient waiting for first kidney transplant * Patients receiving a social security scheme * Postmenopausal women, surgically sterile or subjected to an effective method of contraception * Patient who signed the written consent Exclusion Criteria: * Patients who have been transplanted * Pregnant women * Emergency situation Patients * Patients unable to give consent personally * Major protected Patients * Patients under judicial supervision
References
Publications (0)
Data not yet available